REFERENCIAS

1)Peggs K,Immune reconstitution following Haematopoietic Stem Cell Transplantation, British Journal of Haematology,2004,124,407-420.

2)Ljungman P,Beta-Herpes virus challenges in the transplant recipient,J Infect Dis,2002,186,599.

3)Boeckh M,Long term care after Hematopoietic cell transplantation en adults,NEJM,2002, 347,1625-26.

4)Hombach L,Increased risk of complicated cytomegalovirus infection with the uso of mycophonolate mofetil in allogeneic stem cell transplantation,Bone Marrow Transplantation, 2002,29,903-906.

5)Taylor-Wideman J,Monocytes are a major site of persistence of human cytomegalovirus in peripheral blood mononuclear cells,J Gen Virol,1991,72,2059-2064.

6)Salzberger B,Circulating cytomegalovirus(CMV)-infected endothelial cells en bone marrow transplant patients with CMV disease and CMV infection,J Infect Dis,1997,176,778-781.

7)Shenk T,Differential outcome of human cytomegalovirus infection in primitve hematopoietic cell subpopulation,Blood,2004,104,3,687-695.

8)Ljungman P,Definitions of cytomegalovirus infection and disease in Transplant Recipients, Clin Infect Dis,2002,34,1094-1097.

9)Torok-Storb B,Association of specific cytomegalovirus genotypes with death from myelosuppression after Marrow Transplantation,Blood,1997,90,2097-2102.

10)Coaquette A,Mixed cytomegalovirus glycoprotein B genotypes in immunocompromised patients,Clin Infect Dis,2004,39-155-61.

11)Lowance D,Valacyclovir for the prevention of cytomegalovirus disease after renal transplantation.International Valacyclovir cytomegalovirus Prophylaxis Study Group,NEJM, 1999,340,1462-70.

12)Grattam MT,Cytomegalovirus infection is associated with cardiac allograft rejection and atherosclerosis,JAMA,1989,261,3561-3566.

13)Tollemar J,Variables predicting deep fungal infection in bone marrow transplant recipients, Bone Marrow Transplantation,1989,4,635-641.

14)Torok-Storb B,Cytomegalovirus mediated myelossuppression,J Clin Virol,2002,25(Suppl 2), 51.

15)Hopkins HA,Cytomegalovirus inhibits CD14 expression in human alveolar macrophagos, J Infect Dis,1996,174,69-74.

16)Boeckh M,Immunusuppressive effects of Beta Herpesvirus,Herpes,2003,10,12-16.

17)Gautheret-Dejean A,Human Herpesvirus(HHV)-6 and HHV-7:Two closely related virus with different infection profiles in Stem Cell Transplantation Recipients,J Infect Dis, 2003, 187,179-86.

18)Singh N,Interactions between viruses in transplant recipients,Clin Infect Dis,2005,40,430-436.

19)Emery VC,The dynamics of human cytomegalovirus replication in vivo,J Exp Med, 1999, 190,177-182.

20)Emery VC,Application of viral-load Kinetics to identify patients who develop cytomegalovirus disease after transplantation,Lancet,2000,355,2032-2036.

21)Armstrong D,Infections diseases,Philadelphia,PA:Mosby 1999.

22)Boeckh M,Cytomegalovirus pp65 antigenemia-guided early treatment with ganciclovir versus ganciclovir at engraftment after allogeneic marrow transplantation:a randomized double-blind study,Blood,1996,88,4063-4071.

23)Appelbaum FR,Nonbacterial nonfungal pneumonia following marrow transplantation in 100 identical twins,Transplantation,1982,33,265-268.

24)Wingard JR,Cytomegalovirus infection after autologous bone marrow transplantation with comparison to infection after allogeneic bone marrow transplantation,Blood,1988,71,1432-1437.

25)Meyers JD,Risks factors for cytomegalovirus infection after human marrow transplantation,J Infect Dis,1986,153,478-488.

26)Boeckh M,The impact of cytomegalovirus serostatus of donor and recipient before hematopoietic stem cell transplantation in the era of antiviral prophylaxis and preemptive therapy,Blood,2004,103,2003-2008.

27)Ljungman P,Donor CMV serologic status and outcome of CMV-seropositive recipients after unrelated donor stem cell transplantation:an EBMT megafile analysis,Blood,2003,102,425-4260.

28)Garrett Nichols W,High risk of death due to bacterial and fungal infection among cytomegalovirus(CMV)seronegative recipients of stem cell transplants from seropositive donors:evidence for indirect effects of primary CMV infection,J Infect Dis,2002,185,273-282.

29)Ljungman P,Results of differents strategies for reducing cytomegalovirus-associated mortality in allogeneic stem cell trasnplant recipients,Transplantation,1998,66,1330-1334.

30)Junghanss C,Incidence and outcome of cytomegalovirus infection following nonmyeloablative compared with myeloablative allogeneic stem cell transplantation,a matched control study,Blood,2002,99,1978-1985.

31)Chakrabarti S,High incidence of cytomegalovirus infection after nonmyeloablative stem cell transplantation:potential role of CAMPATH-1H in delaying inmune reconstitution,Blood,2002,99,4357-4363.

32)Hebart H,Risk of cytomegalovirus disease in patients receiving polymerase chain reaction-based preemptive therapy after allogeneic stem cell transplantation depends on transplantation modality,Blood,2001,97,2183-2185.

33)Goldberg S,Unusual viral infections(progressive multifocal leukoencephalopathy and cytomegalovirus disease) after high dose chemotherapy with autlogous blood stem cell rescue and peritransplantation rituximab,Blood,99,1486-1488.

34)Holmberg L,Increased incidence of cytomegalovirus disease after autologous CD34-selected peripheral blood stem cell transplantation,Blood,1999,94,4029-4035.

35)Boeckh M,Late cytomegalovirus disease and mortality in recipients of allogeneic hematopoietic stem cell transplants:importance of viral load and T-cell inmunity,Blood,2003, 101,407-414.

36)Einsele H,Risk factors for treatment failure in patients receiving PCR-based preemptive therapy for cytomegalovirus infection,Bone Marrow Transplantation,2000,25,757-763.

37)Hakki M,Immune recontitution to cytomegalovirus after allogeneic hematopoietic stem cell transplantation:impact of host factors,drug therapy,and subclinical reactivation,Blood,2003,102,3060-3067.

39)Crippa F,Virological,clinical and ophtalmological features of cytomegalovirus retinitis after hematopoietic stem cell transplantation,Clin Infect Dis,2001,32,214-219.

39)Wolf D,Emergence of late cytomegalovirus central nervous system disease in hematopoietic stem cell transplant recipients,Blood,2003,101,463-465.

40)Meyers JD,Cytomegalovirus excretion as a predictor of cytomegalovirus disease after marrow transplantation :importance of CMV viremia.J Infect Dis,1990,162,373-380.

41)Schmidt GM,A randomized,controled trial of prophylactic ganciclovir for cytomegalovirus pulmonary infection in recipients of allogeneic bone marrow transplants,The City of Hope Stanford-Syntex Study Group,NEJM,1991,324,1005-1011.

42)Einsele H,Polymerase chain reaction monitoring reduces the incidence of cytomegalovirus disease and the duration and side effects of antiviral therapy after bone marrow transplantation,Blood,1995,86,2815-2820.

43)Razonable RR,The clinical use of various blood compartments for cytomegalovirus DNA quantitation in transplant recipients with cytomegalovirus disease,Transplantation,2002,73,968-973.

44)Limaye AP,Cytomegalovirus DNA load in plasma for diagnosis of CMV disease before engraftment in hematopoietic stem cell transplant recipients,J Infect Dis,2001,183,377-382.

45)Boeckh M,Plasma polymerasa chain reaction for cytomegalovirus DNA after allogeneic marrow transplantation:comparison with polymerasa chain reaction using peripheral blood leukocytes,pp65antigenemia,and viral culture,Transplantation,1997,64,108-113.

46)Boeckh M,Successful modification of a pp65 antigenemia based early treatment strategy for prevention of cytomegalovirus disease in allogeneic bone marrow transplant recipients,Blood,1999,93,1781-1782.

47)Bowden RA,CMV immunoglobulin and seronegative blood products to prevent primary CMV infection after marrow transplantation,NEJM,1986,314,1006-1010.

48)Miller WJ,Prevention of CMV infection following bone marrow transplantation:a randomized trial of blood product screening,Bone Marrow Transplantation,1991,7,227-234.

49)Ljungman P,Risk of CMV transmission by blood products to immuncompromised patients and means for reduction,British Journal Hematology,2004,125,107-116.

50)Bowden RA,A comparison of filtered leukocyte reduced and CMVseronegative blood products for the prevention of transfusion-associated CMV infection after marrow transplant,Blood,1995,86,3598-3603.

51)Nichols WG,Transfusion-transmitted CMV infection after receipt of leukoreduced blood products,Blood,2003,101,4195-4200.

52)Centers for Disease Control and Prevention,Infecious Disease Society of America,American Society of Blood and Marrow Transplantation.Guidelines for preventing opportunistic infections among hematopoietic stem cell transplant recipients,MMWR,Morb Mortal Wkly Rep 2000,49,1-125.

53)Bowden RA,CMV-specific intravenous immunoglobulin for the prevention of primary CMV infection and disease after marrow transplant,J Infect Dis,1991,164,483-487.

54)Ruutu T,No prevention of CMV infection by anti-CMV hyperimmune globulin in seronegative bone marrow transplant recipients.The Nordic BMT Group,Bone Marrow Transplantation,1997,19,233-236.

55)Bass E,Efficacy of immune globulin in preventing complications of bone marrow transplantation:a metaanalysis,Bone Marrow Transplantation,1993,12,179-183.

56)Meyers JD,Acyclovir for prevention of CMV infection and disease after allogeneic marrow transplantation,NEJM,1988,318,70-75.

57)Boeckh M,Failure of high-dose acyclovir for prevention of CMVdisease after autologous marrow transplant,J Infect Dis,1995,172,939-943.

58)Prentice HG,Impact of long term acyclovir on CMV infection and survival after allogeneic bone marrow transplantation,Lancet,1994,343,749-753.

59)Prentice HG,Long term survival in allogeneic bone marrow transplant recipients following acyclovir prophylaxis for CMV infection.The European Acyclovir for CMV prophylaxis Study Group,Bone Marrow Transplatation,1997,19,129-133.

60)Boeckh M,Effect of high dose acyclovir on survival in allogeneic marrow transplant recipients who received ganciclovir al engraftment or for CMV pp65 antigenemia,J Infect Dis, 1998,178,1153-1157.

61)Ljungman P,Randomized study of valacyclovir as prophylaxis against CMVreactivation in recipients of allogeneic bone marrow transplants,Blood,2002,99,3050-3056.

62)Goodrich JM,Ganciclovir prophylaxis to prevent CMV disease after allogeneic marrow transplant.Ann Int Med,1993,118,173-178.

63)Winston DJ,Ganciclovir prophylaxis of CMV infection and disease in allogeneic bone marrow transplant recipients.Results of a placebo controled doble blind trial,Ann Int Med, 1993,118,179-184.

64)Salzberger B,Neutropenia in allogeneic marrow transplant recipients receiving ganciclovir for prevention of CMV disease:risk factors and outcome,Blood,1997,90,2502-2508.

65)Przepiorka D,Ganciclovir three times per week is not adequate to prevent CMV reactivation after T-cell depleted marrow transplantation,Bone Marrow Transplantation,1994,13,461-464.

66)Verdonck LF,A risk adapted approach with a short course of ganciclovir to prevent CMV pneumonia in CMV seropositive recipients of allogeneic bone marrow transplants,Clin Infect Dis,1997,24,901-907.

67)Winston DJ,Randomized comparison of oral valacyclovir and intravenous ganciclovir for prevention of CMV disease after allogeneic bone marrow transplantation,Clin Infect Dis,2003,36,749-758.

68)Baillie MG,Pharmacokinetics of antiviral agents for the treatment of CMVinfection,Am J Health Syst Pharm,2005,62(Suppl 1) 514-517.

69)Reusser P,Phase I-II trial of foscarnet for prevention ofCMV infection in autologous and allogeneic marrow transplant recipients,J Infect Dis,1992,166,473-479.

70)BacigalupoA,CMV prophylaxis with foscarnet in allogeneic bone marrow transplant recipients at high risk of developing CMV infection,Bone Marrow Transplantation,1994,13,783-788.

71)Aversa F,Treatment of High risk acute leukemia with T-cell depleted stem cells from related donors with one fully mismatched HLA haplotype,NEJM,1998,339,1186-1193.

72)Boeckh M,CMVdisease before hematopoietic cell transplantation as a risk for complications after transplantation,Biol Bon Marr Transp,2005,11,136-148.

73)Schmidt GM,A randomized control trial of prophylactic ganciclovir for cytomegalovirus pulmonary infection in recipients of allogeneic bone marrow transplant,NEJM,1991,324,1005-1011.

74)Goodrich JM,Early treatment with ganciclovir to prevent CMV disease after allogeneic bone marrow transplantation,NEJM,1991,325,1601-1607.

75)Reusser P,Randomized multicenter trial of foscarnet versus ganciclovir for preemptive therapy of CMV infection after allogeneic stem cell transplantation,Blood,2002,99,1159-1164.

76)Griffiths P,A randomized ,controlled trial comparing ganciclovir to ganciclovir plus foscarnet(each at half doses) for preemptive therapy of CMV infection in transplant recipients, J Infect Dis,2004,189,135-1361.

77)Spielberger R,Use of oral ganciclovir for the preventive treatment of CMV following allogeneic HCT:safety and feasibility results.Blood,2000,96,(abstr.586).

78)Ljungman P,Cidofovir for cytomegalovirus infection and disease in allogeneic stem cell transplant recipients,Blood,2001,97,388-392.

79)Reed EC,Treatment of CMV pneumonia with ganciclovir and intravenous CMVimmunoglobulin in patients with bone marrow transplants,Ann Int Med,1988,109,783-788.

80)Schmidt GM,Ganciclovir/immunoglobulin combination therapy for the treatment of human CMV-associated interstitial pneumonia in bona marrow allograft recipients,Transplantation,1988,46,905-907.

81)Emanuel D,CMV pneumonia after bone marrow transplantation succesfully treated with the combination of ganciclovir and high-dose intravenous immune globulin,Ann Int Med , 109,717-782.

82)Ljungman P,Use of intravenous immune globulin in addition to antiviral therapy in the treatment of CMV gastrointestinal disease in allogeneic bone marrow transplanta recipients, Bone Marrow Transplantation,1996,17,813-817.

83)Limaye AP,High incidence of ganciclovir-resistant CMV infection among lung transplant recipients receiving preemptive therapy,J Infect Dis,2002,185,20-27.

84)Limaye AP,Emergence of ganciclovir resistant CMV disease among recipients of solid organ transplants.Lancet,2000,356,645-649.

85)Slavin MA,Ganciclovir sensitivity of CMV at diagnosis and during treatment of CMV pneumonia in marrow transplant recipients,Antimicrob Agents Chemother,1993,37,1360-1363.

86)Gilbert C,Lack of emergence of CMV UL 97 mutations conferring ganciclovir resistance following preemptive ganciclovir therapy in allogeneic stem cell transplant recipients, Antimicrob Agents Chemother,2001,45,3669-3671.

87)Erice A,Ganciclovir susceptibilities and analysis of UL 97 region in CMV isolates from bone marrow recipients with CMV disease after antiviral prophylaxis.J Infect Dis,1998,178,531-534.

88)Nichols WG,Rising pp65 antigenemia during preemptive anticytomegalovirus therapy after allogeneic hematopoietic stem cell transplantation:risk factors,correlation with DNA load, and outcome,Blood,2001,97,867-874.

89)Eckle T,Drug-resistant human CMV infection in children after allogeneic stem cell transplantation may have different clinical outcomes,Blood,2000,96,3286-3289.

90)Boivin G,Rate of emergence of CMV mutations in leukocytes of patients with acquired immunodeficiency syndrome who are receiving valganciclovir as induction and maintenance therapy for CMV retinitis,J Infect Dis,184,1598-1602.

91)Gerna G,Rising antigenemia levels may be misleading in pre-emptive therapy of human CMV  infection in allogeneic hematopoietic stem cell transplant recipients,Haematologica,2005,90,526-533.

92)Boeckh M,Rising CMV pp 65 antigenemia and DNA levels during preemptive antiviral therapy,Haematologica,2005,90,439.